Cerus Corporation

Cerus Corporation is a biomedical products company focused on commercializing the INTERCEPT Blood System to enhance blood safety. The INTERCEPT system is designed to reduce the risk of transfusion-transmitted diseases by inactivating a broad range of pathogens such as viruses, bacteria and parasites that may be present in donated blood. The nucleic acid targeting mechanism of action enables INTERCEPT treatment to inactivate established transfusion threats, such as hepatitis B and C, HIV, West Nile virus and bacteria, and is designed to inactivate emerging pathogens such as influenza, malaria and dengue. Cerus currently markets and sells the INTERCEPT Blood System for both platelets and plasma in Europe, Russia, the Middle East and selected countries in other regions around the world. The INTERCEPT red blood cell system is in clinical development.
Company Growth (employees)
Type
Public
HQ
Concord, US
Size (employees)
204 (est)+16%
Cerus Corporation is headquartered in Concord, US

Key People at Cerus Corporation

William M. Greenman

William M. Greenman

President and CEO
Kevin D. Green

Kevin D. Green

VP, Finance & CFO
Laurence M. Corash

Laurence M. Corash

SVP, CMO & CSO

Cerus Corporation Office Locations

Cerus Corporation has offices in Concord, Amersfoort
Concord, US
Amersfoort, NL

Cerus Corporation Metrics

Cerus Corporation Summary

Market capitalization

$431.5 m

Closing share price

$4.2
Cerus Corporation's current market capitalization is $431.5 m.

Cerus Corporation Financials

Cerus Corporation's revenue is $39.3 m in FY, 2016 which is a 14.8% increase from the previous period.
FY, 2013FY, 2014FY, 2015FY, 2016

Revenue

$39.7 m$36.4 m$34.2 m$39.3 m

Revenue growth, %

(8.2%)(6%)14.8%

Net Income

($43.3 m)($38.8 m)($55.9 m)($62.9 m)

Cerus Corporation Market Value History

Cerus Corporation Company Life

You may also be interested in